Hepatitis C. Chronic viral hepatitis C
Conditions
Interventions
Treatment with daily single-dose of Daclasfovir Shari® (400 mg Sofosbuvir/60 mg Daclatasvir) made in Shari/Bakhtar Bioshimi Co (BBpharmaco) for 12 weeks..
Sponsors
Kerman University of Medical Sciences
National Institute for Medical Research Development
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Being male or female (including transgender) Being 18 years or older at the time of baseline interview Self-reported drug injection with verification for non-medical purposes in the past twelve months Having chronic infection of HCV as confirmed by HCV-RNA Having lived for at least six months in Kerman and have no plan to move out for another three months Having written informed consent to participate in the study Understanding the Farsi language
Exclusion criteria
Exclusion criteria: Cirrhosis HBV/HCV Coinfection Pregnant woman TB/HCV Coinfection eGFR<30 mL/min or chronic renal failure Drug-drug interactions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained Virologic Response. Timepoint: 12 weeks after termination of treatment. Method of measurement: HCV RNA using sensitive RT-PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment uptake. Timepoint: At the study entry. Method of measurement: Acceptance to be treated.;Treatment Adherence. Timepoint: 12 weeks of treatment. Method of measurement: Pill count. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Armita Shahesmaeili
Kerman University of Medical Sciences
Outcome results
None listed